Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,957

The DOI matches its Crossref record; 192 of the 192 references it cites were found in a registry or an index.

Tumor microenvironment as a therapeutic target in cancer

Open access
Xiao, Yi, Yu, Dihua·2021·Pharmacology & Therapeutics

Abstract

Tumor microenvironment denotes the non-cancerous cells and components presented in the tumor, including molecules produced and released by them. The constant interactions between tumor cells and the tumor microenvironment play decisive roles in tumor initiation, progression, metastasis, and response to therapies. The tumor microenvironment as a therapeutic target in cancer has attracted great research and clinical interest. Here we summarize the current progress in targeting the tumor microenvironment in both drug development and clinical trials; highlight challenges in targeting the tumor microenvironment to achieve therapeutic efficacy; explore new technologies and approaches to better decipher the tumor microenvironment; and discuss strategies to intervene in the pro-tumor microenvironment and maximize therapeutic benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2020.107753

Cites

192 of 192 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 192 references

Research works printed but not linked: 6

  1. Chen, 2019, Turning foes to friends: Targeting cancer-associated fibroblasts, Nature Reviews Drug Discovery, 18, 99, 10.1038/s41573-018-0004-1 · DOI · Paper page
  2. Leon-Cabrera, 2019, Inflammation as a target in cancer therapy, Mediators of Inflammation, 2019, 1, 10.1155/2019/1971698 · doi:10.1155/2019/1971698
  3. Moss, 2012, A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer, Gastrointestinal Cancer Research, 5, 77
  4. Nagy, 2019, Quantitative image profiling of the tumor microenvironment on double stained immunohistochemistry images using deep learning, Journal of Clinical Oncology, 37, e14619, 10.1200/JCO.2019.37.15_suppl.e14619 · doi:10.1200/jco.2019.37.15_suppl.e14619
  5. Ward, 2019, Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC), Annals of Oncology, 30, 10.1093/annonc/mdz437.032 · doi:10.1093/annonc/mdz437.032
  6. Wiesweg, 2019, Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer, Annals of Oncology, 30, 655, 10.1093/annonc/mdz049 · doi:10.1093/annonc/mdz049

Cited by

See all 1,957

Metadata

Authors
Xiao, Y., & Yu, D.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2021-05
Volume
221
Pages
107753
ISSN
0163-7258 (ISSN-L)
OpenAlex
W3109885192
Cited by
1,957
References
192
FWCI
43.71
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • METAvivor
  • Duncan Family Institute for Cancer Prevention and Risk Assessment
  • National Institutes of Health (R01CA208213, R01-CA112567-06, P30CA016672, R01CA184836, 56675)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor microenvironment as a therapeutic target in cancer. https://app.cochat.ai/papers/10.1016/j.pharmthera.2020.107753
The paper
Xiao, Y., & Yu, D. (2021). Tumor microenvironment as a therapeutic target in cancer. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2020.107753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.